ResearcherUniversity of BernActive in the last 2 years
Mathias Worni
Matched on ORCID iD 0000-0001-9422-431X; OpenAlex author ID A5058837062. Sources: ClinicalTrials.gov.
Their work
- Papers
- 7 (first author 0, last author 3)
- Trials
- 1 (principal investigator on 1)
- Grants
- 0
- Labs led
- 0
- Collaborators
- 15
2013: 2 papers · 2014: none · 2015: none · 2016: 1 trial · 2017: none · 2018: 2 papers · 2019: none · 2020: 2 papers · 2021: none · 2022: none · 2023: none · 2024: 1 paper
Papers 7
- Local ablative therapies and the effect on antitumor immune responses in pancreatic cancer - A review. Co-author DOI 10.1016/j.heliyon.2023.e23551↗
- Role of lymphadenectomy, adjuvant chemotherapy, and treatment at high-volume centers in patients with resected pancreatic cancer-a distinct view on lymph node … Last author DOI 10.1007/s00423-020-01859-2↗
- Role of lymphadenectomy in resectable pancreatic cancer. Last author DOI 10.1007/s00423-020-01980-2↗
- Tumour budding in pancreatic cancer revisited: validation of the ITBCC scoring system. Co-author DOI 10.1111/his.13508↗
- Integrated Genomic and Immunophenotypic Classification of Pancreatic Cancer Reveals Three Distinct Subtypes with Prognostic/Predictive Significance. Co-author DOI 10.1158/1078-0432.ccr-17-3401↗
- Trends in racial disparities in pancreatic cancer surgery. Last author DOI 10.1007/s11605-013-2304-4↗
- Modest improvement in overall survival for patients with metastatic pancreatic cancer: a trend analysis using the surveillance, epidemiology, and end results r… Co-author DOI 10.1097/mpa.0b013e318291fbc5↗
Trials 1
- Quality of Life After in Situ IRE in Locally Advanced Pancreatic Cancer Principal investigator NCT02926040↗
Closest collaborators
The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Suna Erdem · 3 shared papers, 2020–2024 · strength 0.52
- Paper Local ablative therapies and the effect on antitumor immune responses in pancreatic cancer - A review. DOI 10.1016/j.heliyon.2023.e23551↗
- Paper Role of lymphadenectomy in resectable pancreatic cancer. DOI 10.1007/s00423-020-01980-2↗
- Paper Role of lymphadenectomy, adjuvant chemotherapy, and treatment at high-volume centers in patients with resected pancreat… DOI 10.1007/s00423-020-01859-2↗
- Rebekah Ruth White · 4 shared papers, 2013–2024 · strength 0.49
- Paper Local ablative therapies and the effect on antitumor immune responses in pancreatic cancer - A review. DOI 10.1016/j.heliyon.2023.e23551↗
- Paper Role of lymphadenectomy in resectable pancreatic cancer. DOI 10.1007/s00423-020-01980-2↗
- Paper Modest improvement in overall survival for patients with metastatic pancreatic cancer: a trend analysis using the surve… DOI 10.1097/mpa.0b013e318291fbc5↗
- Beat Gloor · 5 shared papers, 2013–2020 · strength 0.35
- Paper Role of lymphadenectomy, adjuvant chemotherapy, and treatment at high-volume centers in patients with resected pancreat… DOI 10.1007/s00423-020-01859-2↗
- Paper Tumour budding in pancreatic cancer revisited: validation of the ITBCC scoring system. DOI 10.1111/his.13508↗
- Paper Integrated Genomic and Immunophenotypic Classification of Pancreatic Cancer Reveals Three Distinct Subtypes with Progno… DOI 10.1158/1078-0432.ccr-17-3401↗
- Jayanth S. Shankara Narayanan · 1 shared paper, 2024 · strength 0.28
- Martin Wartenberg · 2 shared papers, 2018 · strength 0.17
- Eva Karamitopoulou · 2 shared papers, 2018 · strength 0.17
- René Warschkow · 1 shared paper, 2020 · strength 0.11
- Dan German Blazer · 1 shared paper, 2020 · strength 0.11
- Bruno Martin Schmied · 1 shared paper, 2020 · strength 0.11
- Daniel P. Nussbaum · 1 shared paper, 2020 · strength 0.11
- Alessandro Lugli · 1 shared paper, 2018 · strength 0.09
- Erik Vassella · 1 shared paper, 2018 · strength 0.08
- Aurel A. Perren · 1 shared paper, 2018 · strength 0.08
- Dieter Koeberle · 1 shared paper, 2013 · strength 0.04
- Anand Shah · 1 shared paper, 2013 · strength 0.04
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.